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Abstract Objective Studies have demonstrated that
hypertension remains inadequately managed throughout
the world, with lack of adherence to BP-lowering medi-
cation being a major factor. The aim of the present study
was to evaluate if a pharmaceutical care program could
improve antihypertensive medication adherence and blood
pressure control. Setting This study was conducted in a
secondary care hypertension/dyslipidemia outpatient clinic
in the university teaching hospital of Cova da Beira Hos-
pital Centre, Covilha ˜, located in the Eastern Central Region
of Portugal. Method This report evaluates the pharmacist’s
interventions during a prospective randomised controlled
trial, from July 2009 to June 2010. Patients with diagnosis
of essential hypertension attending the clinic for routine
follow-up were randomly allocated either to a control
group (no pharmaceutical care) or to an intervention group
(quarterly follow-up by a hospital pharmacist during a 9-
month period). The pharmacist interventions, aimed to
increase medication adherence and blood pressure control,
involved educational interventions and counselling tips
directed to the patient. Main outcome measure Systolic
blood pressure, diastolic blood pressure and blood pressure
control (according to JNC 7 guidelines) assessed at the
baseline visit and at the end of pharmaceutical care were
the main outcome measures. Blood pressure measurements
were performed by blinded nurses. Medication adherence
was also evaluated, using a validated questionnaire at
baseline and at the end of investigation. Results A total of
197 hypertensive patients were randomly assigned to the
study (99 in the control group and 98 in the intervention
group). Although there were no signiﬁcant differences
(P[0.05) in both groups concerning mean age, gender,
body mass index, and antihypertensive pharmacotherapy,
blood pressure control was higher in the intervention group
(P = 0.005) at the end of the study. Signiﬁcant lower
systolic blood pressure (-6.8 mmHg, P = 0.006) and
diastolic blood pressure (-2.9 mmHg, P = 0.020) levels
were observed in the intervention group. Medication
adherence was also signiﬁcantly higher in the intervention
group at the end of the study (74.5% vs. 57.6%,
P = 0.012).Conclusion Pharmacist intervention can sig-
niﬁcantly improve medication adherence and blood pres-
sure control in patients treated with antihypertensive
agents.
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Impact of ﬁndings on practice
• Clinical hospital pharmacists can complement physi-
cians in the management of hypertensive patients.
• Pharmacist interventions are effective in improving
antihypertensive medication adherence and reducing
systolic and diastolic blood pressure.
• Clinical pharmacists can effectively participate in
health education and promotion to improve blood
pressure control.
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Hypertension is a major risk factor in the development of
cardiovascular disease and an important public health
problem worldwide. It is estimated that over three million
Portuguese adults (about 30% of the Portuguese popula-
tion) suffer from hypertension. In a recently published
survey [1] only 11.2% hypertensives had their blood
pressure (BP) controlled. This ﬁgure is even lower in the
Central Region of Portugal, where only 9.7% of the total
number of hypertensives have their BP controlled [1].
Although the treatment of hypertension has been shown to
prevent cardiovascular disease and to extend and enhance
life [2, 3], hypertension remains inadequately managed
throughout the world, with lack of adherence to BP-low-
ering medication being a major factor [4–7]. Hypertensive
patients may fail to take their medication because of the
symptomless nature of the condition, the long duration of
therapy, side effects of medication, complicated drug reg-
imens, lack of understanding about hypertension manage-
ment and risks, and costs of medication [8, 9].
Antihypertensive medication adherence rates have differed
widely depending on the population studied and it is esti-
mated to range between 50 and 70% [6, 10, 11].
The importance of improving adherence to antihyperten-
sivemedicationhasbeenaddressedby‘‘Theseventhreportof
the Joint National Committee on prevention, detection,
evaluation and treatment of high BP’’ (JNC 7) [2]a n d
emphasis has been put on the role of all health care profes-
sionals to improve adherence to treatment [2]. Previous
studies have shown that introducing pharmaceutical care to
hypertensive patients in community pharmacies improved
medication adherence and patient outcomes [12–16]. How-
ever,thistypeofcareforhypertensiveoutpatientsinahospital
setting, where collaboration between physician and pharma-
cist is more feasible, has not previously been undertaken in
Portugalandthestudypresentedhereisuniqueinthisrespect.
Aim of the study
The objectives of the present study were to evaluate the
hospital clinic pharmacist’s interventions during a pro-
spective randomised controlled clinical trial (RCT), aimed
to improve antihypertensive medication adherence and BP
control in hypertensive patients in the ambulatory sec-
ondary care setting.
Method
This was a RCT, with participants individually randomised
to one of two parallel groups (allocation ratio 1:1). Eligible
participants were all adults aged 18 or over with an estab-
lished medical diagnosis of arterial hypertension, whether
their BP was controlled or not. According to the JNC 7
guidelines, BP control was deﬁned as BP measurements in
theclinicofsystolicBP(SBP)\140 mmHganddiastolicBP
(DBP)\90 mmHg for patients without diabetes or chronic
kidney disease (CKD) and of SBP \130 mmHg and DBP
\80 mmHg for patients with diabetes or CKD. Further-
more, all included patients had been on established antihy-
pertensive drug treatment for at least 6 months. Exclusion
criteria were dementia, pregnancy and breastfeeding. The
study was carried out from July 2009 to June 2010 in a
hypertension/dyslipidemia clinic in the university hospital
of Cova da Beira Hospital Centre, Covilha ˜, located in the
EasternCentralRegionofPortugal.Thestudywasapproved
by the institutional Ethics Committee for the use of humans
inresearch,andwritteninformedconsentwasobtainedfrom
all participants before their enrollment in the study.
Outpatients attending the medical clinic for routine
follow-up were randomly allocated either to a control
group [(CG) usual care, where no pharmaceutical care is
provided] or to an intervention group [(IG) pharmaceutical
care, consisting of quarterly follow-up by a hospital clinical
pharmacist during a 9-month period]. Participants were
allocated following simple randomisation procedures
(equal allocation and without restrictions) using a com-
puter-generated list of random numbers. The allocation
sequence was concealed from the clinical pharmacist
enrolling and assessing participants in sequentially num-
bered, opaque, sealed envelopes. The computer generated
the allocation sequence and the envelopes were prepared
by a researcher with no clinical involvement in the trial.
Based on the nature of the intervention, it is not feasible to
blind hypertensive patients in pharmaceutical intervention
models. Thus, whereas patients, pharmacists and physi-
cians were aware of the patient allocated arm, nurses
assessing BP were kept blinded to the allocation.
The pharmaceutical care provided to the IG by a clinical
pharmacist consisted in the baseline visit (lasting approxi-
mately 30 min) and the follow-up visits (lasting approxi-
mately 20 min) conducted with each intervention patient at
3and 6 months. The clinical pharmacistcouldalso schedule
additional optional visits between scheduled visits at his
discretion. At each visit, the clinical pharmacist conducted a
thorough interview of the patient, identiﬁed problems
leading to poor BP control, provided patient education
(hypertension education, BP self-monitoring recommenda-
tion,goalBPtoachieve,lifestyleeducationandcounselling,
medication education and counselling tips to enhance
adherence), and presented recommendations to the physi-
cian regarding changes in drug therapy. The recommended
lifestyle changes for BP control were in accordance with the
JNC 7 guidelines [2]. Patients in the IG were also provided
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123with written educational material about hypertension and
possiblecomplications,aswellashealthylifestylepractices.
Furthermore intervention patients were encouraged to bring
all empty blisters and boxes of antihypertensive medication
to clinic visits for recycling and to verify compliance to
therapy. The CG had no clinical pharmacist involvement
andcontrolpatientsreceivedthetraditionalserviceprovided
by the hospital clinic.
The primary outcome measures with respect to pharma-
ceutical care efﬁcacy were the proportion of patients
achieving BP control and reduction in baseline SBP and
DBP. The BP clinic measurement was performed by trained
nurses blind to the study, according to the published
guidelines on proper BP measurement issued by the Portu-
guese Society of Hipertension [17]. Validated automatic BP
measuring devices (Omron M4-I, validated by the British
Society of hypertension [18]) and appropriate cuffs were
used, the mean of two consecutive measurements being
recorded. The secondary outcome measure was antihyper-
tensive medication adherence, which was determined in
both arms by a pharmacist using a validated ﬁve-item
adherence scale [19, 20], derived from the four-item scale
developed by Morisky et al. [21, 22]. Low medication
adherence was deﬁned as answering yes to 3 or more of 5
questions [23]. Patient knowledge of target BPvalues andof
hypertension risks were also evaluated. Patients were con-
sideredknowledgeableoftargetBPvaluesiftheyknewboth
target BP ﬁgures (\140/\90 mmHg for hypertensive
patients without diabetes and CKD and\130/\80 mmHg
for hypertensive patients with diabetes or CKD). They were
considered knowledgeable of the negative impacts of
hypertension to health if they mentioned at least two
potential major negative consequences of uncontrolled
hypertension to health. SBP and DBP levels, BP control,
medication adherence, patient knowledge of target BP val-
ues and of hypertension risks of both groups were assessed
andcomparedatbaselineandattheendofa9-monthperiod.
In the ﬁnal study visit (9-month) the IG did not receive
pharmaceutical care and both arms had BP measured by a
research nurse, and had medication adherence assessed by a
pharmacist. If a subject failed to attend the exit visit despite
multiple contact attempts (i.e., drop out), the last available
clinic BP was extracted for intention-to-treat (ITT) analysis.
Clinical data for this study, including BP measures,
medications prescribed and medical problems were pro-
spectively obtained from the hospital electronic medical
records (HEMR) database. The HEMR database is com-
prised of detailed patient-level clinical and administrative
information from all patients that have used the hospital at
least once. This database is authorized by the Portuguese
government and patient data conﬁdentiality was ensured.
To detect a reduction in SBP of 8–10 mmHg [standard
deviation (SD) 16–18 mmHg], which is in agreement with
several studies, with a two-sided 5% signiﬁcance level and
a power of 80%, a sample size of 90 patients per group
(180 total) was necessary, given an anticipated dropout rate
of 10%. To recruit this number of patients a 3-month (July–
September 2009) inclusion period was anticipated.
Demographic variables, clinical data, medication adher-
ence and BP values of patients included in the study, as well
as prescribing metrics were examined on a descriptive basis
and expressed as the mean ± SD, frequency and percent-
ages. Student’s test and Mann–Whitney rank sum test were
used to compare continuous variables and v
2 test and Fisher
exact probability test were used to test for differences
between categorical variables. All statistical analyses were
done using SPSS for Windows, version 17.0 (SPSS Inc.,
Chicago, IL) and a P-value\0.05 was considered to indi-
cate statistical signiﬁcance.
Results
A total of 222 patients attended the medical clinic during
the recruitment period (from July 2009 to September 2009)
and all were assessed for eligibility. Of these, 17 were
excluded from the study because they did not meet the
inclusion criteria, 1 was excluded because of breastfeeding
and 7 were excluded because they declined to participate.
Of the 197 hypertensive patients meeting the inclusion
criteria and consenting to participate, 99 were allocated to
usual care (CG) and 98 were allocated to pharmaceutical
care (IG) (Fig. 1).
The IG and CG were comparable with respect to age,
gender, education, marital status, body mass index, smok-
ing status, prevalence of chronic illness, number of anti-
hypertensive drugs per patient, and number of years in
antihypertensive treatment (Table 1).
The percentage of patients on angiotensin II receptor
antagonists was the only signiﬁcant difference detected
between the two groups at baseline (Table 2).
Baseline SBP and DBP, BP control, stage 1 and stage 2
hypertension and medication adherence did not signiﬁ-
cantly differ in both groups either (Table 3).
As seen in Fig. 1, a total of 7 subjects (3.6%) withdrew
from the study following allocation, 4 (2.0%) from the
intervention arm and 3 (1.5%) from the control arm. In the
IG, 95 completed the 3-month visit, and 94 completed the
6-month as well as the ﬁnal study visit. The clinical
pharmacist scheduled a mean ± SD of 0.6 ± 0.6 addi-
tional visits per patient in the IG, involving a total of 51
patients (7 patients had 2 additional visits).
At the beginning of the study, only 30 of 98 (30.6%)
patients in the IG had both SBP and DBP controlled. This
was not signiﬁcantly different from the number in the
CG, where 35 of 99 (35.4%) patients had their BP
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123controlled (P = 0.480). At the end of the study, BP was
controlled among signiﬁcantly more patients in the IG
(66.0%) than in the CG (41.7%) (P = 0.0008), with an
odds ratio of 2.7 (95% CI, 1.5–4.9) (Table 3).
The SBP was reduced by 0.8 mmHg in the CG and
7.6 mmHg in the IG (P = 0.005 for between-group SBP
comparison). The DBP was reduced by 1.1 mmHg in the
CG and 3.0 mmHg in the IG (P = 0.016 for between-
group DBP comparison) (Table 3).
A sensitivity analysis to determine the robustness of our
ﬁndings in the presence of informative dropout was per-
formed. The analysis was repeated under the most pessi-
mistic scenario in which all 4 dropouts in the IG had
uncontrolled BP and all 3 dropouts in the CG had con-
trolled BP. In this situation, the respective BP control rates
would be 63.3 and 43.4% (odds ratio of 2.2; 95% CI
1.3–4.0; P = 0.005). Similarly, if we consider the last
available clinic BP extracted in all 7 dropouts, SBP was
reduced by 0.9 mmHg in the CG and 7.4 mmHg in the IG
(P = 0.006 for between-group SBP comparison). The
DBP was reduced by 1.0 mmHg in the CG and 2.7 mmHg
in the IG (P = 0.020 for between-group DBP comparison)
(Table 3).
The intervention pharmacist made 118 recommenda-
tions about antihypertensive therapy, of which 90 (76.3%)
were accepted by physicians. These recommendations
included maintaining current antihypertensive medication
(54.2%), introduction of additional medication (25.4%),
dosage increase of existing medication (13.5%), cessation
of current medication (5.9%) and dosage decrease of
existing medication (0.8%). Despite these recommenda-
tions, the mean of overall changes in antihypertensive
medication did not differ in IG and CG (0.65 vs. 0.72
changes per subject in the IG and CG, respectively,
P = 0.693), neither did the number of new antihyperten-
sive medications (0.34 vs. 0.37, P = 0.768) or the number
of discontinued antihypertensive medications (0.20 vs.
0.19, P = 0.879). Likewise, the mean ± SD number of
antihypertensive medications was not different between the
IG (2.8 ± 1.3 medications) and the CG (2.7 ± 1.4
medications) at the end of the study (P = 0.682). Simi-
larly, the antihypertensive medications prescribed did not
Assessed for eligibility (n=222) 
Excluded  (n=25) 
♦   Not meeting inclusion criteria (n=17) 
5 had been on antihypertensive 
medication for less than 6 months 
5 had diagnosis of arterial hypertension 
but were not prescribed antihypertensives 
7 had diagnosis of dyslipidemia but not 
arterial hypertension 
♦   Declined to participate (n=7) 
♦   Other reasons (breastfeeding) (n=1) 
Analysed  (n=99) 
(99 patients were included in the intent-to-treat 
analyses: SBP, DBP, BP control, medication 
adherence) 
Lost to follow-up (did not completed the 9-
month final study visit) (n=3) 
Allocated to control group (n=99) 
(all patients allocated to control group did not 
receive pharmaceutical intervention)
Lost to follow-up (4 patients did not completed 
the 9-month final study visit; 3 of them 
completed the baseline visit only and 1 
completed the 3-month visit only) (n=4) 
Allocated to intervention group (n=98) 
(all patients allocated to intervention group 
received pharmaceutical intervention) 
Analysed  (n=98) 
(98 patients were included in the intent-to-treat 
analyses: SBP, DBP, BP control, medication 
adherence) 
Allocation
Analysis
Follow-Up
Randomized (n=197) 
Enrollment
Fig. 1 Flow diagram of
patients through the study
protocol (according to
CONSORT 2010 Statement).
BP blood pressure, DBP
diastolic blood pressure, SBP
systolic blood pressure
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123signiﬁcantly differ in both groups at the end of the study
(Table 2). Body mass index (BMI) did not signiﬁcantly
differ at the end of the study either (end BMI was 29.9 and
29.3 for IG and CG, respectively, P = 0.364) despite the
pharmacist’s recommendation of lifestyle changes.
Baseline low medication adherence did not signiﬁcantly
differ in both groups (53.1% in the IG and 50.5% in the
CG, P = 0.718). However, at the end of the study there
was a signiﬁcant difference (P = 0.0017) in the percentage
of patients with low medication adherence between the IG
(22.3%, within group P\0.0001) and the CG (43.8%,
within group P = 0.345).
Similarly, baseline patient knowledge of target BP val-
ues and of the potential complications of high BP to their
health did not signiﬁcantly differ in both groups (Table 3).
However, at the end of the study there was a signiﬁcant
difference in the percentage of patients reporting correctly
both target BP ﬁgures and hypertension risks (Table 3).
Both differences remained signiﬁcant when data were
assessed by ITT analysis (Table 3).
Discussion
The pharmacist intervention program developed for this 9-
month study resulted in signiﬁcant reduction of SBP and
DBP and in an increase in the proportion of patients with
controlled BP according to JNC-7 guidelines. The odds of
achieving BP target in the IG were 2.7 times higher than
the CG (95% CI, 1.5–4.9; P\0.001). These differences
remained signiﬁcant when data were assessed by ITT
analysis. Among hypertensive patients aged 60–69 years,
the additional 6.8 mmHg reduction in SBP observed in
intervention arm would be expected to yield a 22%
reduction in stroke mortality and a 17% reduction in
mortality from ischemic heart disease [24]. Thus, inclusion
Table 1 Patients
demographics and clinical
characteristics at baseline
(n = 197)
a SD standard deviation
Demographic/clinical Control group
(n = 99)
Intervention group
(n = 98)
P value
Gender, n (%) 0.171
Male 35 (35.4) 44 (44.9)
Female 64 (64.4) 54 (55.1)
Age, mean (SD)
a 60.7 (11.8) 58.3 (11.6) 0.155
Body mass index (kg/m
2), mean (SD) 29.0 (4.7) 29.8 (4.9) 0.261
Married, n (%) 85 (85.9) 75 (76.5) 0.094
Education, n (%) 0.991
Illiterate 5 (5.1) 5 (5.1)
Elementary schooling 79 (79.8) 77 (78.6)
High schooling 10 (10.1) 10 (10.2)
University education 5 (5.1) 6 (6.1)
Current smoker, n (%) 8 (8.1) 9 (9.2) 0.777
Comorbid conditions, n (%)
Cerebrovascular disease 15 (15.2) 11 (11.2) 0.417
Chronic kidney disease 6 (6.1) 5 (5.1) 0.764
Diabetes 18 (18.2) 18 (18.4) 1.000
Heart failure 1 (1.0) 0 (0.0) 1.000
Ischemic heart disease 4 (4.0) 1 (1.0) 0.369
Myocardial infarction 2 (2.0) 1 (1.0) 1.000
Left ventricular hypertrophy 2 (2.0) 3 (3.1) 0.683
Dyslipidemia 70 (70.7) 78 (79.6) 0.149
Metabolic syndrome 3 (3.0) 1 (1.0) 0.621
Obesity (body mass index C 30) 43 (43.4) 40 (40.8) 0.708
Advanced age (C65 years), n (%) 34 (34.3) 30 (30.6) 0.578
None of the above, n (%) 11 (11.1) 8 (8.2) 0.484
Number of antihypertensive drugs per
patient, mean (SD)
2.6 (1.4) 2.7 (1.3) 0.437
Number of years in antihypertensive drug
treatment, mean (SD)
9.1 (6.6) 8.6 (6.4) 0.572
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123of a clinical pharmacist on the hypertension care team
represents one possible strategy to address this important
public health issue.
Previously reported reduction of SBP and DBP levels in
patients receiving pharmaceutical care varied between 6.0
and 31.0 mmHg and 3.0 and 14.2 mmHg, respectively [23,
25, 26]. In the present study, a 7.6/3.0 mmHg reduction
was observed in the IG; this may be partly explained by the
low mean SBP and DBP level of the study population at
baseline (141.8/85.8 mmHg). Indeed, most of those studies
only enrolled hypertensive patients with uncontrolled BP,
contrary to the current study in which all hypertensive
patients taking antihypertensive medications for at least
6 months were included (whether their BP was controlled
or not); this approach is closer to the actual context in
which the pharmacist could work in our clinic. Neverthe-
less, the pharmacist intervention was effective in the
management of BP and was consistent with the chronic
care model in which the hypertension clinic uses team-
based care.
The intervention program reported here resulted in sig-
niﬁcant improvement in antihypertensive medication
adherence, which is a likely reason for better BP control in
the IG because antihypertensive medications additions did
not differ. It must be acknowledged that some studies
reported statistically signiﬁcant improvements in treatment
outcomes (SBP, DBP and/or percentage of participants with
controlled BP at the end of the study) without signiﬁcant
increases in medication adherence [14, 16, 23, 27–30]. This
may be attributed to an intensiﬁcation of antihypertensive
medication and some pharmacist interventions led to a
signiﬁcant improvement in BP control by this mechanism,
i.e., overcoming clinical inertia [23, 29, 30]. However, most
studies that reported a statistically signiﬁcant increase in
medication adherence also reported a statistically signiﬁ-
cant improvement in treatment outcomes, which reveals
that medication adherence is a key factor (although not the
only one) to achieve BP control [12, 13, 15, 31–34]. When
baseline medication adherence is high ([75%), pharmacist
interventions are not likely to ﬁnd a statistically signiﬁcant
improvement in this outcome [14, 23, 28, 30]. In the current
study, the low baseline medication adherence (\50%) made
it feasible for pharmaceutical intervention to have a positive
effect in this outcome and hence in treatment outcomes.
Increase in medication adherence obtained could be
attributed to the hypertension and drug education given to
patients. Lack of knowledge about BP targets, hypertension
complications and the beneﬁts of antihypertensive medi-
cation have been recognized as a barrier to adherence
[35–37].
Several limitations of this study must be mentioned.
First, although RCTs provide the highest internal validity
by controlling confounding bias, their use is limited by
contaminating the CG by contact with the intervention
program. In the present study, randomisation at the patient
level, as opposed to pharmacist or physician, may have
resulted in contamination bias. Several patients in the
CG asked the pharmacist about their goal BP targets and
Table 2 Antihypertensive
medication prescribed to
hypertensive patients at baseline
and at the end of the study
Bold means that there is a
statistically signiﬁcant
difference (P value\0.05)
a Includes last medication
prescribed before the ﬁnal study
visit (including to dropouts)
Antihypertensive drug class Control group (Baseline,
n = 99) (End of study,
n = 99)
a
Intervention group (Baseline,
n = 98) (End of study,
n = 98)
a
P value
Loop diuretics (%) 18.2 11.2 0.168
18.2 12.2 0.247
Thiazide diuretics (%) 59.6 64.3 0.498
63.6 67.3 0.584
Potassium-sparing diuretic (%) 6.1 3.1 0.498
6.1 4.1 0.747
Renin inhibitor (%) 3.0 2.0 1.000
3.0 4.1 0.721
ACE inhibitors (%) 32.3 33.7 0.841
32.3 35.7 0.617
Angiotensin II receptor antagonists (%) 47.5 64.3 0.018
52.5 64.3 0.094
Calcium channel blockers (%) 35.4 45.9 0.131
42.4 44.9 0.729
Beta blockers (%) 47.5 41.8 0.427
47.5 42.9 0.517
Central alpha-2 agonists (%) 8.1 7.1 0.806
8.1 6.1 0.590
Int J Clin Pharm (2011) 33:132–140 137
123about the possible serious consequences of high BP at the
beginning of the study, and, further, physicians in the study
cared for patients in both groups. Although contamination
was considered during the study design, researchers rec-
ognized that it would conservatively represent bias toward
the null hypothesis. Second, the evaluation of BP control
was based on the measurements performed in two single
clinic appointments (baseline and after a 9-month follow-
up period). These BP measurements may or may not be
representative of the adequacy of BP control in hyperten-
sive patients, even though they were performed by blinded
nurses, which contributes to the validity of observed
effects. Third, medication adherence was measured by the
research (not blinded) pharmacist, which is potentially
biased in situations where the patient does not respond with
determination to the questionnaire. Finally, the intervention
was short, lasting only 9 months. Future research should be
of a longer duration to determine if the effect of pharmacist
management of hypertension is sustainable.
Conclusion
Pharmacist intervention can modify factors affecting
adherence, improve adherence and reduce BP levels in
patients treated with antihypertensive agents. This study
suggests that one effective method of improving BP control
is for pharmacists to recognize inadequate hypertension
knowledge and medication adherence and develop strate-
gies that enlist the patient as a participant in the manage-
ment of his/her health. Thereby, this report also reinforces
the pharmacists’ role in improving the health care system,
leading to superior hypertensive patient outcomes.
Table 3 Clinic BP ﬁgures, BP control, antihypertensive medication adherence and knowledge about hypertension (baseline, end of the study and
ITT analysis)
Variable Control group Intervention group P value
Baseline (n = 99) (n = 98)
Baseline SBP, mean (SD), mmHg 141.9 (16.8) 141.6 (16.3) 0.873
Baseline DBP, mean (SD), mmHg 86.4 (11.7) 85.2 (10.2) 0.438
Baseline BP control, n (%) 35 (35.4) 30 (30.6) 0.480
Baseline stage 1 HT, n (%) 39 (39.4) 43 (43.9) 0.522
Baseline stage 2 HT, n (%) 22 (22.2) 20 (20.4) 0.752
Baseline low medication adherence, n (%) 50 (50.5) 52 (53.1) 0.718
Knowledge of target BP values, n (%) 59 (59.6) 58 (59.2) 1.000
Knowledge of hypertension risks, n (%) 54 (54.5) 54 (55.1) 0.920
End of the study (n = 96) (n = 94)
End SBP, mean (SD), mmHg 141.1 (18.0) 134.0 (16.0) 0.005
End DBP, mean (SD), mmHg 85.3 (8.9) 82.2 (8.7) 0.016
End BP control, n (%) 40 (41.7) 62 (66.0) 0.0008
End low medication adherence, n (%) 42 (43.8) 21 (22.3) 0.0017
Knowledge of target BP values, n (%) 61 (63.5) 77 (81.9) 0.005
Knowledge of hypertension risks, n (%) 63 (65.6) 79 (84.0) 0.003
ITT analysis (n = 99) (n = 98)
ITT SBP (includes last value carried forward), mean (SD), mmHg 141.0 (18.0) 134.2 (16.0) 0.006
ITT DBP (includes last value carried forward), mean (SD), mmHg 85.4 (9.1) 82.5 (8.6) 0.020
ITT BP control
a, n (%) 43 (43.4) 62 (63.3) 0.005
ITT low medication adherence
b, n (%) 42 (42.4) 25 (25.5) 0.012
ITT knowledge of target BP values
b, n (%) 64 (64.6) 77 (78.6) 0.030
ITT knowledge of hypertension risks
b, n (%) 66 (66.7) 79 (80.6) 0.026
Bold means that there is a statistically signiﬁcant difference (P value\0.05)
a Admitting that all patients from control group lost to follow-up had their BP controlled at the end of the 9-month study and that all patients
from intervention group lost to follow-up had their BP uncontrolled at the end of the 9-month study
b Admitting that all patients from control group lost to follow-up were adherent and knew target BP values and hypertension risks at the end of
the 9-month study and that all patients from intervention group lost to follow-up were no adherent and did not known target BP values and
hypertension risks at the end of the 9-month study
BP blood pressure, DBP diastolic blood pressure, HT hypertension, ITT intention-to-treat, SBP systolic blood pressure, SD standard deviation
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